EU can do more for patients with smart use of biosimilar medicines

European patients need improved access to biosimilar… 22 April 2021 Fifteen years after the first global approval, biosimilar medicines systemically…
Smart reform of EU pharma and IP legislation key to boosting… 28 June 2022 Generic and biosimilar medicines lower healthcare treatment costs dramatically and…
Smart use of off-patent medicines will be critical to… 7 October 2021 Open
Smart policies will encourage more critical medicines… 26 February 2021 Open